Nodal downstaging is important determinant of survival, particularly after lobectomy. (J Thorac Cardiovasc Surg 2011;141:48-58)”
“Objective: Reports have questioned the oncologic efficacy of video-assisted thoracoscopic surgery when compared with thoracotomy despite similar survival results. In response, we investigated the pattern of recurrent AZD3965 research buy disease and the incidence of second
primary tumors after lobectomy by means of video-assisted thoracoscopic surgery and thoracotomy.
Methods: All patients who underwent lobectomy for clinical stage IA lung cancer determined by means of computed tomographic and positron emission tomographic analysis were identified from a prospective database at a single institution. All patients were selected for video-assisted thoracoscopic surgery or thoracotomy by an individual surgeon. Patients’ characteristics, perioperative results, recurrences, and second primary tumors were recorded. Variables were compared by using Student’s t test, the Pearson chi(2) test, and Fisher’s exact test. A logistic regression model was constructed to identify variables influencing the development of recurrent disease or metachronous tumors.
Results: From 2002 to 2009, 520 patients underwent lobectomy by means of video-assisted thoracoscopic surgery, and 652 underwent
lobectomy by means of thoracotomy. Final pathological stage was similar in the video-assisted thoracoscopic surgery and thoracotomy groups. Logistic regression demonstrated a lower risk (odds ratio, 0.65; P = .01)
of recurrent disease Trichostatin A chemical structure in patients undergoing video-assisted thoracoscopic surgery after adjusting for age, stage, sex, histology, tumor location, and synchronous primary tumors.
Conclusions: Recurrence rates for video-assisted thoracoscopic surgery appear to be at least equivalent to those for thoracotomy. This study supports lobectomy by means of video-assisted thoracoscopic surgery as an oncologically sound technique. (J Thorac Cardiovasc Surg 2011;141:59-64)”
“Objective: Our objective was to evaluate whether platinum concentrations in chest wall tissue and in serum are optimized PI3K inhibitor by intracavitary application of cisplatin loaded to a fibrin carrier compared with cisplatin solution in a randomized setting of a pig model.
Methods: After left-sided pneumonectomy including parietal pleurectomy, pigs were randomly assigned to receive either 90 mg/m(2) cisplatin intracavitary solution (n = 6) or to receive 5 mg cisplatin-fibrin (n = 5) applied on a predefined area of the chest wall. Platinum concentration in serum as well as in chest wall tissue was determined at several early time points until day 5 after treatment. Platinum levels were measured by inductively coupled plasma sector field mass spectrometric detection with a matrix-matched calibration procedure.